Dianthus Therapeutics Upgraded to Strong Buy at Wolfe Research

Analysts see promising future for biotech firm's complement therapy pipeline.

Apr. 10, 2026 at 10:52am

Got story updates? Submit your updates here. ›

A highly detailed, macro-level view of the gears, levers, and mechanisms that make up the heavy, industrial machinery of the banking system, conveying a sense of the institutional infrastructure and technical complexity underlying financial markets.An extreme close-up of the complex inner workings of the financial industry, representing the institutional power and security behind stock market gains.NYC Today

Wolfe Research has upgraded shares of Dianthus Therapeutics (NASDAQ:DNTH) to a strong buy rating, citing the company's promising pipeline of complement-based therapies for severe autoimmune and inflammatory diseases. The upgrade comes after several other analysts have also issued positive ratings and price target increases for Dianthus in recent months.

Why it matters

Dianthus Therapeutics is a clinical-stage biotech company developing a new class of complement-targeted therapies, which have shown potential to treat a range of debilitating autoimmune and inflammatory conditions. The strong buy rating from a respected research firm like Wolfe suggests growing confidence in the company's ability to advance its lead drug candidate DNTH103 through late-stage trials and potentially reach the market.

The details

Wolfe Research cited the positive data and progress of Dianthus' lead drug candidate DNTH103, which is currently in Phase 2 clinical trials for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Several other analysts have also issued buy ratings and increased price targets for Dianthus in recent months, reflecting the market's optimism around the company's complement-based therapeutic approach.

  • Wolfe Research issued the strong buy rating on April 10, 2026.
  • Dianthus Therapeutics reported its latest financial results and clinical updates on March 9, 2026.

The players

Dianthus Therapeutics

A clinical-stage biotechnology company developing complement-targeted therapies for severe autoimmune and inflammatory diseases.

Wolfe Research

A respected equity research firm that covers the healthcare and pharmaceutical sectors.

Got photos? Submit your photos here. ›

What’s next

Investors will be closely watching for Dianthus Therapeutics to provide updates on the progress of its DNTH103 drug candidate as it advances through late-stage clinical trials. The company's next earnings report is expected in early May 2026.

The takeaway

The strong buy rating from Wolfe Research underscores the growing optimism around Dianthus Therapeutics' pipeline of novel complement-based therapies, which could provide new treatment options for patients with debilitating autoimmune and inflammatory disorders if the drugs continue to show promise in clinical trials.